Telix presents prostate cancer trial data showing acceptable safety

June 1, 2026 5:00 PM

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) presented data from Part 1 of its ProstACT Global Phase 3 study at ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found